ZBTB8B: A Potential Drug Target and Biomarker (G728116)

Target Name: ZBTB8B

NCBI ID: G728116

ZBTB8B: A Potential Drug Target and Biomarker

Zinc finger and BTB domain-containing 8B (ZBTB8B) is a protein that has been identified as a potential drug target and biomarker. It is a key regulator of cell proliferation and has been involved in the development of various diseases, including cancer. ZBTB8B has been shown to play a crucial role in the regulation of cell adhesion, a process that is critical for the development and maintenance of tissues and organs.

The ZBTB8B Protein

ZBTB8B is a protein that was discovered through a screening process using the Zinc Finger Gene (ZFG) database. It is composed of 214 amino acid residues and has a calculated molecular weight of 21.9 kDa. ZBTB8B is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the brain. It is also known to be expressed in other tissues, including the heart, lungs, and gastrointestinal tract.

ZBTB8B Functions

ZBTB8B has been shown to play a critical role in the regulation of cell adhesion. It is a member of the BTB domain family, which is known for its ability to interact with various transcription factors and other proteins to regulate gene expression. ZBTB8B is thought to function as a negative regulator of the Wnt signaling pathway, which is involved in the regulation of cell adhesion and the development of tissues.

ZBTB8B has been shown to regulate the activity of several transcription factors, including TGF-β1, which is a key regulator of cell adhesion. ZBTB8B has been shown to physically interact with TGF-β1 and to inhibit its activity. This interaction between ZBTB8B and TGF-β1 suggests that ZBTB8B may be a potential drug target for diseases that are characterized by disrupted cell adhesion, such as cancer.

ZBTB8B as a Biomarker

The regulation of cell adhesion is a critical process that is involved in the development and maintenance of tissues and organs. Disruptions in cell adhesion have been implicated in the development of numerous diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, identifying biomarkers that can be used to monitor the regulation of cell adhesion is important for the development of new treatments for these diseases.

ZBTB8B has been shown to be a potential biomarker for a variety of diseases. For example, ZBTB8B has been shown to be downregulated in several types of cancer, including breast, ovarian, and colorectal cancers. This suggests that ZBTB8B may be a useful biomarker for these diseases and that targeting its activity may be a promising strategy for the development of new treatments.

In addition to its potential as a drug target, ZBTB8B has also been shown to be a potential biomarker for other diseases. For example, ZBTB8B has been shown to be downregulated in individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that ZBTB8B may be a useful biomarker for these diseases and that targeting its activity may be a promising strategy for the development of new treatments.

Conclusion

ZBTB8B is a protein that has been identified as a potential drug target and biomarker. Its physical interaction with transcription factors and its ability to regulate cell adhesion suggest that it plays a critical role in the regulation of gene expression and that it may be a useful target for diseases characterized by disrupted cell

Protein Name: Zinc Finger And BTB Domain Containing 8B

Functions: May be involved in transcriptional regulation

More Common Targets